Medtronic Sees Unusually Large Options Volume (NYSE:MDT)

Key Points

• Medtronic experienced a **297% increase** in call options trading, with **45,531 call options** acquired on Friday, significantly surpassing the typical volume of 11,462.
• Despite this trading surge, Medtronic's stock dipped **0.6%** to **$93.64**, with a year high of **$99.37** and a market cap of **$120.11 billion**.
• The company recently declared a quarterly dividend of **$0.71 per share**, yielding **3.0%**, with a payout ratio of **78.24%**.

Medtronic PLC (NYSE:MDT - Get Free Report) was the recipient of unusually large options trading activity on Friday. Investors acquired 45,531 call options on the company. This represents an increase of 297% compared to the typical volume of 11,462 call options.

Medtronic Stock Down 0.6%

MDT stock traded down $0.57 during trading on Friday, hitting $93.64. 1,031,277 shares of the stock traded hands, compared to its average volume of 7,509,249. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. The stock has a market cap of $120.11 billion, a price-to-earnings ratio of 25.79, a price-to-earnings-growth ratio of 2.53 and a beta of 0.78. The firm's 50 day moving average is $94.31 and its two-hundred day moving average is $89.25. Medtronic has a 1 year low of $79.29 and a 1 year high of $99.37.

Medtronic (NYSE:MDT - Get Free Report) last posted its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.03. The business had revenue of $8.58 billion for the quarter, compared to analysts' expectations of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business's revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, sell-side analysts anticipate that Medtronic will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 17th. Shareholders of record on Friday, September 26th were issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend was Friday, September 26th. Medtronic's dividend payout ratio (DPR) is 78.24%.

Insider Buying and Selling

In other news, EVP Harry Skip Kiil sold 8,605 shares of the business's stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the sale, the executive vice president directly owned 35,615 shares in the company, valued at approximately $3,261,621.70. The trade was a 19.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director William R. Jellison acquired 2,500 shares of the stock in a transaction dated Monday, August 25th. The stock was acquired at an average price of $92.37 per share, with a total value of $230,925.00. Following the completion of the acquisition, the director owned 5,000 shares in the company, valued at approximately $461,850. The trade was a 100.00% increase in their position. The disclosure for this purchase can be found here. Insiders own 0.26% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Riverbend Wealth Management LLC boosted its stake in Medtronic by 3.2% during the third quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company's stock worth $332,000 after buying an additional 107 shares during the period. Wynn Capital LLC boosted its stake in Medtronic by 2.4% during the third quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company's stock worth $442,000 after buying an additional 110 shares during the period. Meridian Investment Counsel Inc. boosted its stake in Medtronic by 0.4% during the third quarter. Meridian Investment Counsel Inc. now owns 28,268 shares of the medical technology company's stock worth $2,692,000 after buying an additional 110 shares during the period. Saxony Capital Management LLC boosted its stake in Medtronic by 3.8% during the third quarter. Saxony Capital Management LLC now owns 3,046 shares of the medical technology company's stock worth $290,000 after buying an additional 112 shares during the period. Finally, Cape Investment Advisory Inc. boosted its stake in Medtronic by 3.2% during the second quarter. Cape Investment Advisory Inc. now owns 3,605 shares of the medical technology company's stock worth $314,000 after buying an additional 113 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

MDT has been the subject of a number of recent analyst reports. Wall Street Zen lowered shares of Medtronic from a "buy" rating to a "hold" rating in a report on Friday, October 3rd. Wolfe Research upgraded shares of Medtronic from an "underperform" rating to a "peer perform" rating in a report on Monday, June 30th. Needham & Company LLC reaffirmed a "hold" rating on shares of Medtronic in a research report on Thursday, August 14th. Mizuho upped their target price on shares of Medtronic from $98.00 to $100.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 16th. Finally, BTIG Research reaffirmed a "neutral" rating on shares of Medtronic in a research report on Friday, July 11th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $102.82.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.